Dr. Halis Kaan Akturk

I am happy to announce that I received 2024 @TheAACE (American Association of Clinical Endocrinology) Rising Star in Endocrinology Award for contributions in type 1 diabetes and diabetes technologies. Thank you and I appreciate this honor.

At #ATDC2025 I discussed GMI vs. uGMI vs. HbA1c vs. eA1c vs. TIR vs. TING What should be used in glycemic control ?

Dr. DeFronzo summarized the benefits of GLP-1 analogs. #ATDC2025 Drs. Phillip and Sherr are chairing. GLP-1 and SGLT-2 are mainstay in diabetes management unless otherwise indicated.

Read our recent study on cannabis use in type 1 diabetes and it is commonly misdiagnosed as gastroparesis and how to differentiate cannabis related symptoms vs gastroparesis in people with type 1 diabetes.

A good start to #Endo2025 to talk about CGMs. Diabetes technologies for everyone.

Just received my Clinical Decision Algorithms in Diabetes book by @Drhkakturk . Can’t wait to keep learning from you—this time through your book!

My first book with Dr. Shah is published from American Diabetes Association. It will be a great pocket reference for clinicians taking care of people with diabetes. @ADA_DiabetesPro You can purchase from shopdiabetes.org/collections/pr…

.@TandemDiabetes' t:slim X2 Now Compatible With FreeStyle Libre 3 Plus Tandem recently announced that its t:slim X2 insulin pump with Control-IQ+ AID technology now works with @AbbottNews' FreeStyle Libre 3 Plus CGM sensor in the U.S.

Halls Kaan Akturk, MD, prepares the #ADA2025 audience for the presentation of the ADJUST-T1D trial of semaglutide 1 mg on top of auto insulin delivery in patients with T1D. Stay tuned for more! #ADASciSessions

We reported the first long term double blind study of Semaglutide in type 1 diabetes. Semaglutide is effective in reducing weight, insulin dose and HbA1c in type 1 diabetes.

Presenting your #ADA2025 Technology Planning Committee! It was a honor and pleasure to work alongside our team ⁦@PriyaPrahalad⁩ and ⁦⁦@Drhkakturk⁩

Looking forward to seeing you #ADA2025

TING (70-140 mg/dL) and TIR (70-180 mg/dL) are greater indicators for diabetic complications at #ADA2025 by @TBattelino Time to retire HbA1c and use CGM metrics for follow up.

First study from @VertexPharma published @NEJM for stem cell for type 1 diabetes

Insulet’s Omnipod 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Life Science Report lifesciencereport.com/news/nasdaq/po…

I and Viral Shah are happy to announce that our pocket book "Clinical Decision Algorithms in Diabetes" is going to be launched at the #ADA2025 in Chicago from American Diabetes Association Press. We spent almost a year and converted entire ADA Standards of Care into flow charts.

Dr. Zaharieva @5Dess is talking on how to manage exercise in different AID systems in people with type 1 diabetes at the EPIC patient conference for diabetes. #EPIC2025 #EpiConf2025 Thanks for coming @5Dess and it was a great talk.

Interoperability in CGM is the key . All pumps should connect to all CGM. Users should make the decision.

Simplera Sync is FDA approved @MDT_Diabetes . It will connect to 780G. It’s the new CGM from Medtronic.

New Libre App is available ! The Libre app works with FreeStyle Libre 2 and FreeStyle Libre 3 family of sensors. Now one app for all sensors. @FreeStyleDiabet

🚨BREAKING: Lilly’s oral GLP-1, orforglipron, hits its primary endpoint in the Phase 3 ACHIEVE-1 trial for type 2 diabetes. 🔸A1C↓ by 1.3–1.6% 🔸Weight loss: up to 16 lbs (7.9%) 🔸65%+ hit A1C ≤6.5% Once-daily, oral small molecule GLP-1—no food/water restrictions Safety…